Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss First Quarter Fiscal Year 2024 Financial Results
Aurora Spine Corporation Schedules Conference Call to Update Investors and Discuss First Quarter Fiscal Year 2024 Financial Results
CARLSBAD, Calif. , May 13, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results that ended March 31, 2024. Management will host the conference call on Tuesday May 14, 2024 at 11:00 a.m. Eastern Time.
加利福尼亞州卡爾斯巴德，2024年5月13日（GLOBE NEWSWIRE）——改善脊柱手術結果的創新醫療器械的設計師和製造商Aurora Spine Corporation（“Aurora Spine” 或 “公司”）（TSXV：ASG）（OTCQB：ASAPF）今天宣佈，計劃舉行電話會議，向投資者通報最新情況，並討論截至2024年3月31日的2024財年第一季度財務業績。管理層將於美國東部時間2024年5月14日星期二上午11點主持電話會議。
First Quarter Fiscal Year 2024 Conference Call Details
2024財年第一季度電話會議詳情
Date and Time: Tuesday May 14, 2024, at 11:00 a.m. ET / 8:00 a.m. PT
日期和時間：美國東部時間 2024 年 5 月 14 日星期二上午 11:00 /太平洋時間上午 8:00
Call-in Information: Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-5794.
電話信息：有興趣的人士可以通過撥打 (844) 861-5497 或 (412) 317-5794 來參加電話會議。
Webcast: Interested parties can access the conference call via a live webcast, which is available via the following link:
網絡直播：感興趣的各方可以通過網絡直播觀看電話會議，該直播可通過以下鏈接獲得：
Replay: A teleconference replay of the call will be available until May 21, 2024, at (877) 344-7529 or (412) 317-0088, replay access code 9427446. Additionally, a replay of the webcast will be available at for 90 days.
重播：電話會議的電話會議重播將持續到2024年5月21日，電話：（877）344-7529或（412）317-0088，重播訪問代碼爲9427446。此外，網絡直播的重播將在 90 天內播出。
About Aurora Spine
關於奧羅拉脊柱
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at .
Aurora Spine致力於通過一系列創新的微創再生脊柱植入技術爲脊柱植入物市場提供新的解決方案。更多信息可在以下網址獲取。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險投資交易所及其監管服務提供商（該術語在多倫多證券交易所風險交易所的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
Forward-Looking Statements
前瞻性陳述
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
本新聞稿包含前瞻性信息，涉及大量已知和未知的風險和不確定性，其中大多數是Aurora Spine無法控制的，包括但不限於Aurora Spine最終招股說明書中 “風險因素” 和 “關於前瞻性信息的警示聲明” 中列出的信息（統稱爲 “前瞻性信息”）。本新聞稿中的前瞻性信息包括有關公司產品在外科手術中的擬議用途和成功的信息。Aurora Spine提醒Aurora Spine證券的投資者注意一些重要因素，這些因素可能導致Aurora Spine的實際業績與本新聞稿中包含的任何前瞻性陳述中的預測存在重大差異。任何表達預期、信念、計劃、目標、假設或未來事件或業績或涉及討論的陳述都不是歷史事實，可能是前瞻性的，可能涉及估計、假設和不確定性，可能導致實際結果或結果與此類前瞻性陳述中表達的結果或結果存在單方面差異。無法保證此處提出的預期會被證明是正確的，因此，潛在投資者不應過分依賴這些前瞻性陳述。這些聲明僅代表截至本新聞稿發佈之日，Aurora Spine 不承擔任何更新或修改聲明以反映新事件或情況的義務。
Contact:
聯繫人：
Aurora Spine Corporation
奧羅拉脊柱公司
Trent Northcutt
特倫特·諾斯卡特
President and Chief Executive Officer
總裁兼首席執行官
(760) 424-2004
(760) 424-2004
Chad Clouse
查德·克勞斯
Chief Financial Officer
首席財務官
(760) 424-2004
(760) 424-2004
譯文內容由第三人軟體翻譯。